Editorial
Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?
Abstract
Stage III non-small cell lung cancer (NSCLC) remains a clinical challenge with only modest improvements in treatment over two decades and a plateau in survival.
